Clinical Trial Update: MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing MabionCD20 to MabThera/Rituxan in rheumatoid arthritis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• MabThera (rituximab)
• MabionCD20 (MabionCD20)
• Rituxan (rituximab)

Snippet

Sponsor: Mabion SA | Conditions: Rheumatoid Arthritis | Phase 3 | Status: WITHDRAWN